Abstract: Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.

Abstract: The present disclosure relates to PI3Ka inhibitors, the crystalline forms, salts, and cocrystals thereof, and the compositions and methods of making and use thereof.

Abstract: Aspects of the subject disclosure may include, for example, receiving, over a network, a registration request (e.g., an IMS registration request) from a communication device; obtaining, by the network device over the network from a network server, information indicating enabled services associated with the communication device; and providing, by the network device over the network, a request successful message to the communication device, where the request successful message includes the information indicating the enabled services. Other embodiments are disclosed.

Abstract: A method for identifying a producing area of Rizhao green tea is provided to identify Rizhao green tea in a trace amount accurately, conveniently, and rapidly, providing a new theoretical method and scientific basis for tracing the producing area of the Rizhao green tea. The method includes the following steps: S1, collection and preprocessing of tea leaf samples; S2, thermogravimetric analysis-Fourier transform infrared spectroscopy (TGA-FTIR) coupled testing; S3, infrared spectrogram analysis; S4, thermogravimetric-differential thermogravimetric spectrogram analysis; S5, estimation of kinetic parameters of the Rizhao green tea; S6, calculation of the pyrolysis parameters of the Rizhao green tea; and S7, establishment of an Ea prediction model for Rizhao green tea. A prediction model is established for the activation energy Ea of a Rizhao green tea leaf sample Y1, and an input to the prediction model is merely three characteristic parameters. The problem of model complexity is fundamentally solved.

Abstract: Provided in the present invention are a high-plasticity steel and a manufacturing method therefor. The steel comprises the following components in percentage by mass: C: 0.10-0.35%, Si: 0.8-2.0%, Mn: 1.0-3.0%, P: ?0.02%, S ?0.005%, Al: 0.1-2.0%, N: ?0.005%, with the balance being Fe and other inevitable impurities. The steel of the present invention can achieve good matching among a low yield strength, a low yield ratio, a high tensile strength and an ultrahigh elongation rate, and can be widely applied to components with complex shape requirements, or other parts that require thinning while maintaining high strength, such as those in commercial or passenger vehicles.

Abstract: Described herein are compounds of Formula 1 or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.

Abstract: Aspects of the subject disclosure may include, for example, executing an OTT application; and providing an API that enables the OTT application to connect with a native SIP stack of the device, where the OTT application negotiates with a network server for one or more QoS parameters for a communication service provided via the OTT application. Other embodiments are disclosed.

Abstract: The present invention discloses a polymorphic form of a chalcone glycoside compound, and a preparation method and an application thereof in a medicament for treating a vascular disease. The chalcone glycoside compound has a structure of the general formula below or a hydrate thereof, where R1 and R2 are ?-D-glucosyl or ?-D-glucosyl; R3 is hydrogen or hydroxyl; and M is a metal ion, and n is 1-2. The chalcone glycoside compound described in the present invention can effectively inhibit platelet aggregation, has a protective effect against cell apoptosis, can significantly relieve ischemia/ischemia-reperfusion injury, increases a serum SOD content, and improves behavior disorders and tissue infarction focuses induced by ischemia-reperfusion. Moreover, this crystal form has a simple process, high purity and excellent stability, and has important significance for developing medicaments for treating vascular diseases with stronger therapeutic effects, lower toxicity and urgent clinical needs.

Abstract: Techniques for validating alignment between network element configuration and DNS records associated with a communication network are presented. Alignment management component (AMC) can retrieve respective configuration parameter data items relating to respective configuration parameters associated with respective resource-related identifiers, and respective metadata items associated with the respective resource-related identifiers, from a configuration data store; and retrieve respective DNS records from respective DNS name servers, based on analyzing the respective metadata items associated with respective DNS records. For each resource-related identifier that is supposed to have a corresponding DNS record, based on the result of analyzing the respective configuration parameter data items and respective DNS records, AMC can determine whether the resource-related identifier has a corresponding DNS record stored in the DNS name server indicated by the metadata item.

Abstract: Aspects of the subject disclosure may include, for example, a method in which a processing system creates a network element by consolidating a control plane including a combination of a plurality of 5G control plane functions and a plurality of IMS control plane functions with an associated user plane including a combination of a 5G user plane function (UPF) and one or more IMS user plane functions. The method also includes deploying the network element at a network edge of the service provider network, receiving a request from a user endpoint (UE) device for a network service, and attaching the UE to the network element. The network element is configured to facilitate providing the requested network service. Other embodiments are disclosed.

Abstract: Aspects of the subject disclosure may include, for example, executing an OTT application; and providing an API that enables the OTT application to connect with a native SIP stack of the device, where the OTT application negotiates with a network server for one or more QoS parameters for a communication service provided via the OTT application. Other embodiments are disclosed.

Abstract: Techniques for validating alignment between network element configuration and DNS records associated with a communication network are presented. Alignment management component (AMC) can retrieve respective configuration parameter data items relating to respective configuration parameters associated with respective resource-related identifiers, and respective metadata items associated with the respective resource-related identifiers, from a configuration data store; and retrieve respective DNS records from respective DNS name servers, based on analyzing the respective metadata items associated with respective DNS records. For each resource-related identifier that is supposed to have a corresponding DNS record, based on the result of analyzing the respective configuration parameter data items and respective DNS records, AMC can determine whether the resource-related identifier has a corresponding DNS record stored in the DNS name server indicated by the metadata item.

Abstract: The presently disclosed subject matter relates to compositions and methods for the generation of stable human embryonic kidney-293 (HEK-293) cell lines for adeno-associated virus (AAV) production.

Abstract: The present invention is directed to substituted certain 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and ring A are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.

Abstract: Aspects of the subject disclosure may include, for example, a device in which a processing system defines service attributes for a function of an internet multimedia subsystem (IMS) core; the function is dedicated for providing a service to a user endpoint (UE) device. The processing system facilitates constructing a resource profile of the IMS core that includes the function; registering the function at a network repository function (NRF) associated with the IMS core; discovering the function from the NRF; obtaining a service requirement of the UE; and matching the service requirement with the service attributes in accordance with matching criteria. Other embodiments are disclosed.

Abstract: Aspects of the subject disclosure may include, for example, a method in which a processing system creates a network element by consolidating a control plane including a combination of a plurality of 5G control plane functions and a plurality of IMS control plane functions with an associated user plane including a combination of a 5G user plane function (UPF) and one or more IMS user plane functions. The method also includes deploying the network element at a network edge of the service provider network, receiving a request from a user endpoint (UE) device for a network service, and attaching the UE to the network element. The network element is configured to facilitate providing the requested network service. Other embodiments are disclosed.

Abstract: The present disclosure generally relates to the expression of T2R taste receptors in eukaryotic cells, such as U2OS cells. The disclosure also relates to methods of expressing T2R taste receptors in such cells, and to methods of screening for substances that modulate T2R receptors, and which, therefore, may be useful as modulators of bitter taste.

Abstract: Aspects of the subject disclosure may include, for example, a device in which a processing system defines service attributes for a function of an internet multimedia subsystem (IMS) core; the function is dedicated for providing a service to a user endpoint (UE) device. The processing system facilitates constructing a resource profile of the IMS core that includes the function; registering the function at a network repository function (NRF) associated with the IMS core; discovering the function from the NRF; obtaining a service requirement of the UE; and matching the service requirement with the service attributes in accordance with matching criteria. Other embodiments are disclosed.

Abstract: Described herein are compounds of Formula (I), or a pharmaceutically acceptable salt thereof. The compounds of Formula (I) act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.

Abstract: The present invention provides methods and compositions for treating a lung or heart disease and/or a disease associated with increased expression or activity of integrin ?5?1, comprising administering an integrin ?5?1, inhibitor to a subject. Methods of treating or preventing pulmonary hypertension, pulmonary arterial hypertension (PAH), right ventricle failure, heart failure and fibrosis are also provided herein.